PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

T-cell targeted therapy tested in type 1 diabetes study

2013-08-28
(Press-News.org) WA, Seattle (August 28, 2013) – Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network (ITN), are published today in The Lancet Diabetes & Endocrinology. The study did not meet its primary endpoint: at 12 months, insulin production, as measured by C-peptide responses, showed no difference in overall decline between the treatment and placebo groups.

Thymoglobulin®, currently licensed for the treatment of organ transplant rejection, is a form of antithymocyte globulin (ATG), a mixture of specialized proteins called antibodies. These antibodies attach themselves to white blood cells known as T cells, interfering with their function and eliminating them temporarily from the bloodstream. During the development of type 1 diabetes, T cells mistakenly destroy the beta cells of the pancreas, which secrete insulin. ITN investigators hypothesized that treating new-onset type 1 diabetes with thymoglobulin would disrupt T-cell activation and might induce tolerance.

The Phase II START study enrolled 58 new-onset type 1 diabetic patients ages 12 to 35 years old. The patients were randomized 2:1 to receive ATG treatment or placebo. Patients in the ATG group received intravenous infusion of ATG over 4 consecutive days at the start of the study; patients in the placebo group received saline solution. At 6-month intervals, researchers measured insulin production of patients in both groups. The study was the first rigorous, placebo-controlled, multicenter study of ATG therapy in patients with new-onset type 1 diabetes.

Further inspection of the ATG treatment group revealed two distinct rates of change during the 12-month period. Most of the decline in beta cell function occurred during the first 6 months. Interestingly, this initial rate of decline in function was limited to younger patients (ages 12 to 21 years old), whereas older patients (above 21 years of age) showed almost no reduction from baseline levels in insulin production over the 12 months. Almost all patients in the treatment group experienced serum sickness and cytokine release syndrome following ATG infusions, and the investigators suggest that this early cytokine induction may have led to the unfavorable loss of beta cell function, particularly in the younger patients.

Analyses of blood samples from START patients revealed that T cells rapidly decreased following ATG administration, consistent with the known mechanism of action of the drug. However, investigators observed notable differences between two specific T-cell subtypes during the first 6 months: the level of effector memory T cells, important mediators of inflammation, did not decline, while the level of regulatory T cells, which are beneficial in suppressing immune attack, were reduced.

Follow-up of subjects in this trial may yield additional insights into differences in response to ATG, and suggest biomarkers of safety and efficacy to be used in future new-onset type 1 diabetes trials. The high-quality clinical specimens collected throughout the study also will be an important resource for uncovering insights about the mechanisms of disease and identifying pathways to target in future studies.

### About The Immune Tolerance Network

The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

Contact: Philip Bernstein, PhD
(240) 235 6132
ITNCommunications@immunetolerance.org
Immune Tolerance Network
Office of the Director
1201 Ninth Avenue
Seattle, WA 98101-2795
206-342-6901


ELSE PRESS RELEASES FROM THIS DATE:

Broccoli could be key in the fight against osteoarthritis

2013-08-28
A compound found in broccoli could be key to preventing or slowing the progress of the most common form of arthritis, according to new research led by the University of East Anglia (UEA). Results from the laboratory study show that sulforaphane slows down the destruction of cartilage in joints associated with painful and often debilitating osteoarthritis. The researchers found that mice fed a diet rich in the compound had significantly less cartilage damage and osteoarthritis than those that were not. The study, which also examined human cartilage cells and cow cartilage ...

Joslin scientists identify genetic variant associated with coronary heart disease in type 2 diabetes

2013-08-28
BOSTON -- August 27, 2013 -- Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients. This discovery has the potential to lead to the development of new treatments for CHD in diabetic patients. The findings appear in the [month] issue of the Journal of the American Medical Association (JAMA). CHD is the leading cause of morbidity and mortality among diabetic ...

Genetic variant identified that may increase heart disease risk among people with type 2 diabetes

2013-08-28
Boston, MA — A newly discovered genetic variant may increase the risk of heart disease in people with type 2 diabetes by more than a third, according to a study led by researchers at Harvard School of Public Health (HSPH) and Joslin Diabetes Center. It is the first genome-wide association study (GWAS) to identify a novel genetic variant associated with coronary heart disease (CHD) in people with type 2 diabetes, who have a two- to four-fold higher risk of heart disease compared with those without diabetes. The finding could lead to new interventions aimed at preventing ...

Zealous imaging fuelling unnecessary and harmful treatment of low risk thyroid cancers

2013-08-28
New technologies such as ultrasound, CT and MRI scanning can detect thyroid nodules as small as 2mm – many of these small nodules are papillary thyroid cancers. In the US, cases have tripled in the past 30 years - from 3.6 per 100,000 in 1973 to 11.6 per 100,000 in 2009 – making it one of the fastest growing diagnoses. Yet the death rate from papillary thyroid cancer has remained stable. This expanding gap between incidence of thyroid cancer and deaths suggests that low risk cancers are being overdiagnosed and overtreated, argue Dr Juan Brito and colleagues at the ...

The extraordinary evolution of REVs

2013-08-28
A new study by Anna Maria Niewiadomska and Robert Gifford, of The Aaron Diamond AIDS Research Center, New York, reveals that reticuloendotheliosis viruses (REVs), which originated in mammals, spread to birds as a result of medical intervention. Their findings will be published August 27 in the open access journal PLOS Biology. "We became intrigued by these viruses", says Gifford, "…because their distribution in nature suggests something very unusual has occurred during their evolution." The reticuloendotheliosis viruses (REVs) are retroviruses that were first identified ...

Size of personal space is affected by anxiety

2013-08-28
The space surrounding the body (known by scientists as 'peripersonal space'), which has previously been thought of as having a gradual boundary, has been given physical limits by new research into the relationship between anxiety and personal space. New findings have allowed scientists to define the limit of the 'peripersonal space' surrounding the face as 20-40cm away. The study is published today in The Journal of Neuroscience. As well as having numerical limits the specific distance was found to vary between individuals. Those with anxiety traits were found to have ...

Combination drug regimen may benefit patients with hepatitis C

2013-08-28
Treatment of chronic hepatitis C virus (HCV) genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA. "Chronic infection with hepatitis C virus is a major cause of chronic liver disease, end-stage liver disease, hepatocellular cancer and remains the leading indication for liver transplants in western countries. The HCV epidemic in the United States is centered in large urban ...

Study examines relationship of a commercial ACO contract with medical spending

2013-08-28
Payment incentives implemented with a commercial accountable care organization (ACO) initiative in Massachusetts –Blue Cross Blue Shield's Alternative Quality Contract (AQC) – were associated with lower spending for Medicare enrollees served by the provider groups participating in the AQC, findings that suggest that evaluations of ACO programs may need to consider the implications for other patient populations to assess their full clinical and economic benefits, according to a study in the August 28 issue of JAMA. "In response to mounting pressures to deliver more cost-effective ...

Genetic variant associated with increased CHD risk in individuals with type 2 diabetes

2013-08-28
Researchers have identified a previously unknown genetic locus (the place a gene occupies on a chromosome) significantly associated with increased coronary heart disease risk among patients with type 2 diabetes, but the association was not found in individuals without diabetes, according to a study in the August 28 issue of JAMA. The variant is functionally related to glutamic acid metabolism, suggesting a mechanistic link. "The prevalence of type 2 diabetes has been steadily increasing in the United States and other countries, with the total number of affected people ...

X-ray of ducts during gallbladder surgery not linked with reduction in risk of common duct injury

2013-08-28
In an analysis of a procedure used to help prevent common duct injury during gallbladder removal surgery, use of intraoperative cholangiography (radiologic examination of the ducts during gallbladder surgery) was not associated with a reduced risk of common duct injury, according to a study in the August 28 issue of JAMA. "Biliary anatomy misidentification during cholecystectomy [gallbladder removal] can result in injury to the common hepatic duct or common bile duct. Common duct injuries cause significant short- and long-term morbidity including major operations, multiple ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] T-cell targeted therapy tested in type 1 diabetes study